The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The blood screening market plays a critical role in ensuring the safety and quality of blood used for transfusions and medical procedures. It involves the detection of infectious agents such as HIV, hepatitis B and C, and other transfusion-transmissible infections, helping to prevent disease transmission. The market is driven by increasing awareness of blood safety, rising demand for blood donations, and technological advancements in screening methods such as nucleic acid testing and rapid diagnostics. With growing healthcare investments and supportive government initiatives, the blood screening market is expanding globally, particularly in emerging economies. As the need for accurate and efficient blood testing continues to rise, the market is expected to experience sustained growth across various healthcare settings.
Tariff Impact Analysis for Blood Screening Market:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation:
The blood screening market is segmented by technology into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, and chemiluminescence immunoassay (CLIA).
Based on product type, the blood screening market includes reagents & kits, instruments, and software solutions.
By end user, the market is divided into blood banks, hospitals, diagnostic laboratories, and plasma centers.
The blood screening market can also be segmented by application such as infectious disease detection, blood group typing, and genetic disorder screening.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Other Players
Market Growth:
The blood screening market is witnessing strong growth due to increasing demand for safe blood transfusions and rising prevalence of infectious diseases such as HIV, hepatitis, and syphilis.
Technological advancements, including nucleic acid testing (NAT) and rapid diagnostic methods, are driving the efficiency and accuracy in the blood screening market.
Growing awareness of blood safety standards and stringent government regulations are further propelling the expansion of the blood screening market.
The rising number of voluntary blood donations and healthcare infrastructure development also support market growth.
Increasing adoption of automation and high-throughput screening platforms is enhancing the scalability of the blood screening market.
Restraining Factors:
High cost of advanced screening technologies can limit adoption in low- and middle-income countries, restraining the blood screening market.
Lack of infrastructure and trained personnel in rural and underdeveloped areas hinders market penetration.
Complex and time-consuming regulatory approvals delay the launch of innovative screening products in the blood screening market.
Variability in testing guidelines and standardization across countries can pose compliance challenges.
Reluctance toward blood donation in certain populations may impact the supply side of the blood screening market.
Regional Analysis:
North America holds a dominant share in the blood screening market due to established healthcare systems, high awareness, and advanced screening facilities.
Europe shows consistent demand driven by strong regulatory policies, technological advancements, and high screening volumes.
Asia-Pacific is emerging as a fast-growing region in the blood screening market, fueled by increasing healthcare investments, awareness campaigns, and government initiatives.
Latin America and the Middle East & Africa are gradually adopting screening technologies, though growth is moderated by limited access and infrastructure.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com